Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPRAISE: Atropine after vitrectomy surgery
NCT07434635Phase 4Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Mar 2026
- Primary completion
- Feb 2028
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of NVK002 in Eye disorders (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Pain score on the Visual Analog Scale (VAS) at 1 month. Started Mar 2026; status: recruiting.
02
Drugs
NVK002
03
Conditions
Eye disorders
Beyond the preview
Go deeper on NCT07434635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07434635.